RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Oronsky, Bryan, Carter, Corey A., Caroen, Scott, Scribner, Curtis, Oronsky, Arnold, Reid, Tony R.
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2020
Témata:
Back Matter
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7790525/
https://ncbi.nlm.nih.gov/pubmed/33457091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1746172
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky